Current Report Filing (8-k)
November 20 2017 - 4:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November 20, 2017
MEDOVEX
CORP.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
001-36763
|
|
46-3312262
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
3060 Royal Boulevard S., Ste 150
Alpharetta, Georgia
|
|
30022
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Ference Kesner LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure
On
November 16, 2017, MedoveX Corporation (the “Company”) issued a press release containing an open letter to the Company’s
shareholders from the Company’s Chief Executive Officer, Jarrett Gorlin. A copy of the press release is attached to this
Current Report as Exhibit 99.1 and shall not be deemed incorporated by reference into any of the Company’s registration
statements or other filings with the Securities & Exchange Commission, except as shall be expressly set forth by specific
reference in such filing.
The
information in this Item 7.01 disclosure, including Exhibits 99.1, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1 and
99.2, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or
the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MEDOVEX
CORPORATION
|
|
|
Date:
November 20, 2017
|
By:
|
/s/
Jarrett Gorlin
|
|
|
Jarrett
Gorlin
|
|
|
Chief
Executive Officer
|